Fri, January 22, 2021
Thu, January 21, 2021
Wed, January 20, 2021
Tue, January 19, 2021
Mon, January 18, 2021
Fri, January 15, 2021
Thu, January 14, 2021
Wed, January 13, 2021

Matthew Harrison Maintained (VRTX) at Hold with Increased Target to $251 on, Jan 19th, 2021


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-increased-target-to-251-on-jan-19th-2021.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Matthew Harrison of Morgan Stanley, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Hold with Increased Target from $249 to $251 on, Jan 19th, 2021.

Matthew has made no other calls on VRTX in the last 4 months.



There are 8 other peers that have a rating on VRTX. Out of the 8 peers that are also analyzing VRTX, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Geoffrey Porges of "SVB Leerink" Maintained at Hold with Decreased Target to $257 on, Friday, October 30th, 2020


These are the ratings of the 7 analyists that currently disagree with Matthew


  • Brian Abrahams of "RBC Capital" Maintained at Buy and Held Target at $265 on, Tuesday, December 8th, 2020
  • Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $288 on, Friday, November 20th, 2020
  • Vincent Chen of "Bernstein" Initiated at Buy and Held Target at $275 on, Friday, November 20th, 2020
  • Evan Seigerman of "Credit Suisse" Maintained at Buy with Decreased Target to $285 on, Friday, October 30th, 2020
  • Gena Wang of "Barclays" Maintained at Buy with Decreased Target to $307 on, Friday, October 30th, 2020
  • Paul Matteis of "Stifel" Maintained at Strong Buy with Decreased Target to $277 on, Friday, October 30th, 2020
  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Decreased Target to $305 on, Thursday, October 15th, 2020

Publication Contributing Sources